{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:18Z","timestamp":1786982178582,"version":"build-2736575974"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s12012-023-09800-x","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T12:03:04Z","timestamp":1689940984000},"page":"233-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Mitochondrial Dysfunction in Cardiotoxicity Induced by BCR-ABL1 Tyrosine Kinase Inhibitors -Underlying Mechanisms, Detection, Potential Therapies"],"prefix":"10.1007","volume":"23","author":[{"given":"Sheng","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiqiu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhoubiao","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehua","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoquan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"issue":"6","key":"9800_CR1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour, E., & Kantarjian, H. (2020). Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. American Journal of Hematology, 95(6), 691\u2013709. https:\/\/doi.org\/10.1002\/ajh.25792","journal-title":"American Journal of Hematology"},{"issue":"3","key":"9800_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/nejm199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl, S., Talpaz, M., Estrov, Z., O\u2019Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999). The biology of chronic myeloid Leukemia. The New England Journal of Medicine, 341(3), 164\u2013172. https:\/\/doi.org\/10.1056\/nejm199907153410306","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"9800_CR3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1200\/jco.1986.4.7.1079","volume":"4","author":"SJ Iacoboni","year":"1986","unstructured":"Iacoboni, S. J., Plunkett, W., Kantarjian, H. M., Estey, E., Keating, M. J., McCredie, K. B., & Freireich, E. J. (1986). High-dose cytosine arabinoside: Treatment and cellular pharmacology of chronic myelogenous Leukemia blast crisis. Journal of clinical oncology\u202f: Official journal of the American Society of Clinical Oncology, 4(7), 1079\u20131088. https:\/\/doi.org\/10.1200\/jco.1986.4.7.1079","journal-title":"Journal of clinical oncology : Official journal of the American Society of Clinical Oncology"},{"issue":"22","key":"9800_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/ijms21228529","volume":"21","author":"J Esteban-Villarrubia","year":"2020","unstructured":"Esteban-Villarrubia, J., Soto-Castillo, J. J., Pozas, J., San Roman-Gil, M., Orejana-Martin, I., Torres-Jimenez, J., Carrato, A., Alonso-Gordoa, T., & Molina-Cerrillo, J. (2020). Tyrosine kinase receptors in oncology. International Journal of Molecular Sciences, 21(22), 48. https:\/\/doi.org\/10.3390\/ijms21228529","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"9800_CR5","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun, T. P., Eide, C. A., & Druker, B. J. (2020). Response and Resistance to BCR-ABL1-Targeted Therapies. Cancer cell, 37(4), 530\u2013542. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.006","journal-title":"Cancer cell"},{"issue":"5","key":"9800_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/jco.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann, R., M\u00fcller, M. C., Lauseker, M., Hanfstein, B., Fabarius, A., Schreiber, A., Proetel, U., Pletsch, N., Pfirrmann, M., Haferlach, C., Schnittger, S., Einsele, H., Dengler, J., Falge, C., Kanz, L., Neubauer, A., Kneba, M., Stegelmann, F., Pfreundschuh, M., \u2026 Hochhaus, A. (2014). Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: Results from the randomized CML-study IV. Journal of Clinical Oncology\u202f: Official Journal of the American Society of Clinical Oncology, 32(5), 415\u2013423. https:\/\/doi.org\/10.1200\/jco.2013.49.9020","journal-title":"Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology"},{"issue":"20","key":"9800_CR7","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes, J. E., Saglio, G., Kantarjian, H. M., Baccarani, M., Mayer, J., Boqu\u00e9, C., Shah, N. P., Chuah, C., Casanova, L., Bradley-Garelik, B., Manos, G., & Hochhaus, A. (2016). Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial. Journal of Clinical Oncology\u202f: Official Journal of the American Society of Clinical Oncology, 34(20), 2333\u20132340. https:\/\/doi.org\/10.1200\/JCO.2015.64.8899","journal-title":"Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology"},{"issue":"2","key":"9800_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/2040620712468289","volume":"4","author":"PK Bhamidipati","year":"2013","unstructured":"Bhamidipati, P. K., Kantarjian, H., Cortes, J., Cornelison, A. M., & Jabbour, E. (2013). Management of imatinib-resistant patients with chronic myeloid leukemia. Therapeutic Advances in Hematology, 4(2), 103\u2013117. https:\/\/doi.org\/10.1177\/2040620712468289","journal-title":"Therapeutic Advances in Hematology"},{"issue":"3","key":"9800_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00280-007-0478-8","volume":"61","author":"AV Kamath","year":"2008","unstructured":"Kamath, A. V., Wang, J., Lee, F. Y., & Marathe, P. H. (2008). Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): A potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemotherapy and Pharmacology, 61(3), 365\u2013376.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"9800_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/637059","author":"M Reinwald","year":"2014","unstructured":"Reinwald, M., Schleyer, E., Kiewe, P., Blau, I. W., Burmeister, T., Pursche, S., Neumann, M., Notter, M., Thiel, E., Hofmann, W.-K., Kolb, H.-J., Burdach, S., & Bender, H.-U. (2014). Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive Leukemia patients with central nervous system relapse after allogeneic stem cell transplantation. BioMed Research International. https:\/\/doi.org\/10.1155\/2014\/637059","journal-title":"BioMed Research International"},{"issue":"7","key":"9800_CR11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40265-014-0216-6","volume":"74","author":"SM Hoy","year":"2014","unstructured":"Hoy, S. M. (2014). Ponatinib: A review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic Leukaemia. Drugs, 74(7), 793\u2013806. https:\/\/doi.org\/10.1007\/s40265-014-0216-6","journal-title":"Drugs"},{"issue":"4","key":"9800_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/ejh.12743","volume":"97","author":"N Gunnarsson","year":"2016","unstructured":"Gunnarsson, N., Sandin, F., H\u00f6glund, M., Stenke, L., Bj\u00f6rkholm, M., Lambe, M., Olsson-Str\u00f6mberg, U., Richter, J., & Sj\u00e4lander, A. (2016). Population-based assessment of chronic myeloid leukemia in Sweden: Striking increase in survival and prevalence. European Journal of Haematology, 97(4), 387\u2013392. https:\/\/doi.org\/10.1111\/ejh.12743","journal-title":"European Journal of Haematology"},{"issue":"1","key":"9800_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","volume":"126","author":"S Saussele","year":"2015","unstructured":"Saussele, S., Krauss, M. P., Hehlmann, R., Lauseker, M., Proetel, U., Kalmanti, L., Hanfstein, B., Fabarius, A., Kraemer, D., Berdel, W. E., Bentz, M., Staib, P., de Wit, M., Wernli, M., Zettl, F., Hebart, H. F., Hahn, M., Heymanns, J., Schmidt-Wolf, I., \u2026 M\u00fcller, M. C. (2015). Impact of comorbidities on overall survival in patients with chronic myeloid Leukemia: Results of the randomized CML study IV. Blood, 126(1), 42\u201349. https:\/\/doi.org\/10.1182\/blood-2015-01-617993","journal-title":"Blood"},{"issue":"6","key":"9800_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-022-00692-8","volume":"12","author":"A Sanz","year":"2022","unstructured":"Sanz, A., Ayala, R., Hern\u00e1ndez, G., Lopez, N., Gil-Alos, D., Gil, R., Colmenares, R., Carre\u00f1o-Tarragona, G., S\u00e1nchez-Pina, J., Alonso, R. A., Garc\u00eda-Barrio, N., P\u00e9rez-Rey, D., Meloni, L., Calbacho, M., Cruz-Rojo, J., Pedrera-Jim\u00e9nez, M., Serrano-Balazote, P., de la Cruz, J., & Mart\u00ednez-L\u00f3pez, J. (2022). Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network. Blood Cancer Journal, 12(6), 94. https:\/\/doi.org\/10.1038\/s41408-022-00692-8","journal-title":"Blood Cancer Journal"},{"issue":"9","key":"9800_CR15","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/jjco\/hyx071","volume":"47","author":"K Tajiri","year":"2017","unstructured":"Tajiri, K., Aonuma, K., & Sekine, I. (2017). Cardiovascular toxic effects of targeted cancer therapy. Japanese Journal of Clinical Oncology, 47(9), 779\u2013785. https:\/\/doi.org\/10.1093\/jjco\/hyx071","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"35","key":"9800_CR16","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/jco.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi, J. J., & Deininger, M. (2015). Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid Leukemia. Journal of Clinical Oncology\u202f: Official Journal of the American Society of Clinical Oncology, 33(35), 4210\u20134218. https:\/\/doi.org\/10.1200\/jco.2015.62.4718","journal-title":"Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology"},{"issue":"2","key":"9800_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.pcad.2010.06.005","volume":"53","author":"QS Wells","year":"2010","unstructured":"Wells, Q. S., & Lenihan, D. J. (2010). Reversibility of left ventricular dysfunction resulting from chemotherapy: Can this be expected? Progress in Cardiovascular Diseases, 53(2), 140\u2013148. https:\/\/doi.org\/10.1016\/j.pcad.2010.06.005","journal-title":"Progress in Cardiovascular Diseases"},{"issue":"4","key":"9800_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ejhf.58","volume":"16","author":"W Maharsy","year":"2014","unstructured":"Maharsy, W., Aries, A., Mansour, O., Komati, H., & Nemer, M. (2014). Ageing is a risk factor in imatinib mesylate cardiotoxicity. European Journal of Heart Failure, 16(4), 367\u2013376. https:\/\/doi.org\/10.1002\/ejhf.58","journal-title":"European Journal of Heart Failure"},{"issue":"9","key":"9800_CR19","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3324\/haematol.2015.129221","volume":"100","author":"G Gugliotta","year":"2015","unstructured":"Gugliotta, G., Castagnetti, F., Breccia, M., Levato, L., D\u2019Adda, M., Stagno, F., Tiribelli, M., Salvucci, M., Fava, C., Martino, B., Cedrone, M., Bocchia, M., Trabacchi, E., Cavazzini, F., Usala, E., Russo Rossi, A., Bochicchio, M. T., Soverini, S., Alimena, G., \u2026 Rosti, G. (2015). Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. Haematologica, 100(9), 1146\u20131150. https:\/\/doi.org\/10.3324\/haematol.2015.129221","journal-title":"Haematologica"},{"issue":"4","key":"9800_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3724\/sp.J.1263.2012.05251","volume":"9","author":"HH Ran","year":"2012","unstructured":"Ran, H. H., Zhang, R., Lu, X. C., Yang, B., Fan, H., & Zhu, H. L. (2012). Imatinib-induced decompensated heart failure in an elderly patient with chronic myeloid leukemia: Case report and literature review. Journal of Geriatric Cardiology: JGC, 9(4), 411\u2013414. https:\/\/doi.org\/10.3724\/sp.J.1263.2012.05251","journal-title":"Journal of Geriatric Cardiology: JGC"},{"issue":"3","key":"9800_CR21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/leu.2016.246","volume":"31","author":"VS Hoffmann","year":"2017","unstructured":"Hoffmann, V. S., Baccarani, M., Hasford, J., Castagnetti, F., Di Raimondo, F., Casado, L. F., Turkina, A., Zackova, D., Ossenkoppele, G., Zaritskey, A., H\u00f6glund, M., Simonsson, B., Indrak, K., Sninska, Z., Sacha, T., Clark, R., Bogdanovic, A., Hellmann, A., Griskevicius, L., \u2026 Hehlmann, R. (2017). Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia, 31(3), 593\u2013601. https:\/\/doi.org\/10.1038\/leu.2016.246","journal-title":"Leukemia"},{"issue":"21","key":"9800_CR22","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1182\/blood.2021011722","volume":"139","author":"E Berman","year":"2022","unstructured":"Berman, E. (2022). How I treat chronic-phase chronic myelogenous Leukemia. Blood, 139(21), 3138\u20133147. https:\/\/doi.org\/10.1182\/blood.2021011722","journal-title":"Blood"},{"issue":"1","key":"9800_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11899-020-00560-x","volume":"15","author":"D Gustafson","year":"2020","unstructured":"Gustafson, D., Fish, J. E., Lipton, J. H., & Aghel, N. (2020). Mechanisms of cardiovascular toxicity of BCR-ABL1 Tyrosine kinase inhibitors in chronic myelogenous Leukemia. Current Hematologic Malignancy Reports, 15(1), 20\u201330. https:\/\/doi.org\/10.1007\/s11899-020-00560-x","journal-title":"Current Hematologic Malignancy Reports"},{"issue":"6","key":"9800_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.beem.2012.05.003","volume":"26","author":"LD Osellame","year":"2012","unstructured":"Osellame, L. D., Blacker, T. S., & Duchen, M. R. (2012). Cellular and molecular mechanisms of mitochondrial function. Best Practice & Research Clinical endocrinology & metabolism, 26(6), 711\u2013723. https:\/\/doi.org\/10.1016\/j.beem.2012.05.003","journal-title":"Best Practice & Research Clinical endocrinology & metabolism"},{"issue":"8","key":"9800_CR25","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkel\u00e4","year":"2006","unstructured":"Kerkel\u00e4, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., Rosenzweig, A., Salomon, R. N., Van Etten, R. A., Alroy, J., Durand, J. B., & Force, T. (2006). Cardiotoxicity of the Cancer Therapeutic Agent Imatinib Mesylate. Nature medicine, 12(8), 908\u2013916. https:\/\/doi.org\/10.1038\/nm1446","journal-title":"Nature medicine"},{"issue":"1","key":"9800_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/toxsci\/kfn157","volume":"106","author":"Y Will","year":"2008","unstructured":"Will, Y., Dykens, J. A., Nadanaciva, S., Hirakawa, B., Jamieson, J., Marroquin, L. D., Hynes, J., Patyna, S., & Jessen, B. A. (2008). Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicological Sciences\u202f: An Official Journal of the Society of Toxicology, 106(1), 153\u2013161. https:\/\/doi.org\/10.1093\/toxsci\/kfn157","journal-title":"Toxicological Sciences : An Official Journal of the Society of Toxicology"},{"issue":"9","key":"9800_CR27","doi-asserted-by":"publisher","first-page":"H1453","DOI":"10.1152\/ajpheart.00554.2015","volume":"309","author":"ZV Varga","year":"2015","unstructured":"Varga, Z. V., Ferdinandy, P., Liaudet, L., & Pacher, P. (2015). Drug-induced mitochondrial dysfunction and cardiotoxicity. American Journal of Physiology Heart and Circulatory Physiology, 309(9), H1453-1467. https:\/\/doi.org\/10.1152\/ajpheart.00554.2015","journal-title":"American Journal of Physiology Heart and Circulatory Physiology"},{"issue":"12","key":"9800_CR28","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1161\/res.0000000000000104","volume":"118","author":"E Murphy","year":"2016","unstructured":"Murphy, E., Ardehali, H., Balaban, R. S., DiLisa, F., Dorn, G. W., 2nd., Kitsis, R. N., Otsu, K., Ping, P., Rizzuto, R., Sack, M. N., Wallace, D., & Youle, R. J. (2016). Mitochondrial function, biology, and role in disease: A scientific statement from the american heart association. Circulation Research, 118(12), 1960\u20131991. https:\/\/doi.org\/10.1161\/res.0000000000000104","journal-title":"Circulation Research"},{"issue":"6","key":"9800_CR29","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.cell.2012.02.035","volume":"148","author":"J Nunnari","year":"2012","unstructured":"Nunnari, J., & Suomalainen, A. (2012). Mitochondria: In sickness and in health. Cell, 148(6), 1145\u20131159. https:\/\/doi.org\/10.1016\/j.cell.2012.02.035","journal-title":"Cell"},{"issue":"3","key":"9800_CR30","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.cell.2015.10.001","volume":"163","author":"GS Shadel","year":"2015","unstructured":"Shadel, G. S., & Horvath, T. L. (2015). Mitochondrial ROS signaling in organismal homeostasis. Cell, 163(3), 560\u2013569. https:\/\/doi.org\/10.1016\/j.cell.2015.10.001","journal-title":"Cell"},{"issue":"22","key":"9800_CR31","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1111\/bph.14431","volume":"176","author":"BY Nguyen","year":"2019","unstructured":"Nguyen, B. Y., Ruiz-Velasco, A., Bui, T., Collins, L., Wang, X., & Liu, W. (2019). Mitochondrial function in the heart: The insight into mechanisms and therapeutic potentials. British Journal of Pharmacology, 176(22), 4302\u20134318. https:\/\/doi.org\/10.1111\/bph.14431","journal-title":"British Journal of Pharmacology"},{"key":"9800_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2018.00055","author":"MG Pouwer","year":"2018","unstructured":"Pouwer, M. G., Pieterman, E. J., Verschuren, L., Caspers, M. P. M., Kluft, C., Garcia, R. A., Aman, J., Jukema, J. W., & Princen, H. M. G. (2018). The BCR-ABL1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model. Frontiers in Cardiovascular Medicine. https:\/\/doi.org\/10.3389\/fcvm.2018.00055","journal-title":"Frontiers in Cardiovascular Medicine"},{"key":"9800_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14071313","author":"X Tang","year":"2022","unstructured":"Tang, X., Wang, Z., Hu, S., & Zhou, B. (2022). Assessing Drug-induced mitochondrial toxicity in cardiomyocytes: Implications for preclinical cardiac safety evaluation. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics14071313","journal-title":"Pharmaceutics"},{"issue":"5 Pt B","key":"9800_CR34","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/j.bbadis.2017.09.004","volume":"1864","author":"W Wang","year":"2018","unstructured":"Wang, W., Fernandez-Sanz, C., & Sheu, S. S. (2018). Regulation of mitochondrial bioenergetics by the non-canonical roles of mitochondrial dynamics proteins in the heart. Biochimica et Biophysica Acta Molecular Basis of Disease, 1864(5 Pt B), 1991\u20132001. https:\/\/doi.org\/10.1016\/j.bbadis.2017.09.004","journal-title":"Biochimica et Biophysica Acta Molecular Basis of Disease"},{"issue":"3","key":"9800_CR35","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.mam.2010.03.002","volume":"31","author":"V Shoshan-Barmatz","year":"2010","unstructured":"Shoshan-Barmatz, V., De Pinto, V., Zweckstetter, M., Raviv, Z., Keinan, N., & Arbel, N. (2010). VDAC, a multi-functional mitochondrial protein regulating cell life and death. Molecular Aspects of Medicine, 31(3), 227\u2013285. https:\/\/doi.org\/10.1016\/j.mam.2010.03.002","journal-title":"Molecular Aspects of Medicine"},{"issue":"2","key":"9800_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41580-021-00415-0","volume":"23","author":"I Vercellino","year":"2022","unstructured":"Vercellino, I., & Sazanov, L. A. (2022). The assembly, regulation and function of the mitochondrial respiratory chain. Nature Reviews Molecular Cell Biology, 23(2), 141\u2013161. https:\/\/doi.org\/10.1038\/s41580-021-00415-0","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"2","key":"9800_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1083\/jcb.200605138","volume":"175","author":"F Vogel","year":"2006","unstructured":"Vogel, F., Bornh\u00f6vd, C., Neupert, W., & Reichert, A. S. (2006). Dynamic subcompartmentalization of the mitochondrial inner membrane. The Journal of cell biology, 175(2), 237\u2013247. https:\/\/doi.org\/10.1083\/jcb.200605138","journal-title":"The Journal of cell biology"},{"key":"9800_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2019.01.017","author":"YP Cao","year":"2019","unstructured":"Cao, Y. P., & Zheng, M. (2019). Mitochondrial dynamics and inter-mitochondrial communication in the heart. Archives of Biochemistry and Biophysics. https:\/\/doi.org\/10.1016\/j.abb.2019.01.017","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"9800_CR39","doi-asserted-by":"publisher","first-page":"739095","DOI":"10.3389\/fcvm.2021.739095","volume":"8","author":"Y Yin","year":"2021","unstructured":"Yin, Y., & Shen, H. (2021). Advances in cardiotoxicity induced by altered mitochondrial dynamics and mitophagy. Frontiers in Cardiovascular Medicine, 8, 739095. https:\/\/doi.org\/10.3389\/fcvm.2021.739095","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"2","key":"9800_CR40","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jacc.2017.05.034","volume":"70","author":"MN Sack","year":"2017","unstructured":"Sack, M. N., Fyhrquist, F. Y., Saijonmaa, O. J., Fuster, V., & Kovacic, J. C. (2017). Basic biology of oxidative stress and the\u00a0cardiovascular system: Part 1 of a 3-Part Series. Journal of the American College of Cardiology, 70(2), 196\u2013211. https:\/\/doi.org\/10.1016\/j.jacc.2017.05.034","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"9800_CR41","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1152\/ajpheart.00253.2014","volume":"309","author":"KH Lauritzen","year":"2015","unstructured":"Lauritzen, K. H., Kleppa, L., Aronsen, J. M., Eide, L., Carlsen, H., Haugen, \u00d8. P., Sjaastad, I., Klungland, A., Rasmussen, L. J., Attramadal, H., Storm-Mathisen, J., & Bergersen, L. H. (2015). Impaired dynamics and function of mitochondria caused by mtDNA toxicity leads to heart failure. American journal of physiology Heart and circulatory physiology, 309(3), 434\u2013449. https:\/\/doi.org\/10.1152\/ajpheart.00253.2014","journal-title":"American journal of physiology Heart and circulatory physiology"},{"key":"9800_CR42","doi-asserted-by":"publisher","first-page":"819454","DOI":"10.3389\/fcvm.2022.819454","volume":"9","author":"M Liu","year":"2022","unstructured":"Liu, M., & Wu, Y. (2022). Role of mitophagy in coronary heart Disease: Targeting the mitochondrial dysfunction and inflammatory regulation. Frontiers in Cardiovascular Medicine, 9, 819454. https:\/\/doi.org\/10.3389\/fcvm.2022.819454","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"9","key":"9800_CR43","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1172\/jci120849","volume":"128","author":"B Zhou","year":"2018","unstructured":"Zhou, B., & Tian, R. (2018). Mitochondrial dysfunction in pathophysiology of heart failure. The Journal of clinical Investigation, 128(9), 3716\u20133726. https:\/\/doi.org\/10.1172\/jci120849","journal-title":"The Journal of clinical Investigation"},{"issue":"1","key":"9800_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/ejhf.654","volume":"19","author":"JL Zamorano","year":"2017","unstructured":"Zamorano, J. L., Lancellotti, P., Rodriguez Mu\u00f1oz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y., Lyon, A. R., Lopez Fernandez, T., Mohty, D., Piepoli, M. F., Tamargo, J., Torbicki, A., Suter, T. M., Zamorano, J. L., Aboyans, V., Achenbach, S., \u2026 Windecker, S. (2017). 2016 ESC Position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: The task force for cancer treatments and cardiovascular toxicity of the european society of cardiology (ESC). European Journal of Heart Failure, 19(1), 9\u201342. https:\/\/doi.org\/10.1002\/ejhf.654","journal-title":"European Journal of Heart Failure"},{"issue":"5","key":"9800_CR45","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nrc2106","volume":"7","author":"T Force","year":"2007","unstructured":"Force, T., Krause, D. S., & Van Etten, R. A. (2007). Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews Cancer, 7(5), 332\u2013344. https:\/\/doi.org\/10.1038\/nrc2106","journal-title":"Nature Reviews Cancer"},{"key":"9800_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232416053","author":"Y Liu","year":"2022","unstructured":"Liu, Y., Huang, Y., Xu, C., An, P., Luo, Y., Jiao, L., Luo, J., & Li, Y. (2022). Mitochondrial dysfunction and therapeutic perspectives in cardiovascular diseases. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms232416053","journal-title":"International Journal of Molecular Sciences"},{"key":"9800_CR47","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.fct.2012.11.055","volume":"53","author":"M Waseem","year":"2013","unstructured":"Waseem, M., & Parvez, S. (2013). Mitochondrial dysfunction mediated cisplatin induced toxicity: Modulatory role of curcumin. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association, 53, 334\u2013342. https:\/\/doi.org\/10.1016\/j.fct.2012.11.055","journal-title":"Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association"},{"key":"9800_CR48","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7582730","author":"S Gorini","year":"2018","unstructured":"Gorini, S., De Angelis, A., Berrino, L., Malara, N., Rosano, G., & Ferraro, E. (2018). Chemotherapeutic drugs and mitochondrial dysfunction: Focus on doxorubicin, trastuzumab, and sunitinib. Oxidative Medicine and Cellular Longevity. https:\/\/doi.org\/10.1155\/2018\/7582730","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"2","key":"9800_CR49","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56(2), 185\u2013229. https:\/\/doi.org\/10.1124\/pr.56.2.6","journal-title":"Pharmacological Reviews"},{"issue":"2","key":"9800_CR50","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10565-018-9425-1","volume":"34","author":"D Wu","year":"2018","unstructured":"Wu, D., Wang, X., & Sun, H. (2018). The role of mitochondria in cellular toxicity as a potential drug target. Cell Biology and Toxicology, 34(2), 87\u201391. https:\/\/doi.org\/10.1007\/s10565-018-9425-1","journal-title":"Cell Biology and Toxicology"},{"key":"9800_CR51","doi-asserted-by":"publisher","first-page":"119607","DOI":"10.1016\/j.lfs.2021.119607","volume":"277","author":"CW Kim","year":"2021","unstructured":"Kim, C. W., & Choi, K. C. (2021). Effects of anticancer drugs on the cardiac mitochondrial toxicity and their underlying mechanisms for novel cardiac protective strategies. Life Sciences, 277, 119607. https:\/\/doi.org\/10.1016\/j.lfs.2021.119607","journal-title":"Life Sciences"},{"key":"9800_CR52","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cbi.2014.10.016","volume":"224","author":"VI Lushchak","year":"2014","unstructured":"Lushchak, V. I. (2014). Free radicals, reactive oxygen species, oxidative stress and its classification. Chemico-Biological Interactions, 224, 164\u2013175. https:\/\/doi.org\/10.1016\/j.cbi.2014.10.016","journal-title":"Chemico-Biological Interactions"},{"issue":"6","key":"9800_CR53","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrm3801","volume":"15","author":"KM Holmstr\u00f6m","year":"2014","unstructured":"Holmstr\u00f6m, K. M., & Finkel, T. (2014). Cellular mechanisms and physiological consequences of redox-dependent signalling. Nature Reviews Molecular cell biology, 15(6), 411\u2013421. https:\/\/doi.org\/10.1038\/nrm3801","journal-title":"Nature Reviews Molecular cell biology"},{"issue":"6","key":"9800_CR54","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/j.tiv.2010.06.009","volume":"24","author":"Z Fu","year":"2010","unstructured":"Fu, Z., Guo, J., Jing, L., Li, R., Zhang, T., & Peng, S. (2010). Enhanced toxicity and ROS generation by doxorubicin in primary cultures of cardiomyocytes from neonatal metallothionein-I\/II null mice. Toxicology in vitro\u202f: An International Journal Published in Association with BIBRA, 24(6), 1584\u20131591. https:\/\/doi.org\/10.1016\/j.tiv.2010.06.009","journal-title":"Toxicology in vitro : An International Journal Published in Association with BIBRA"},{"issue":"8","key":"9800_CR55","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2174\/1389450116666150304103517","volume":"16","author":"CG Tocchetti","year":"2015","unstructured":"Tocchetti, C. G., Molinaro, M., Angelone, T., Lionetti, V., Madonna, R., Mangiacapra, F., Moccia, F., Penna, C., Sartiani, L., Quaini, F., & Pagliaro, P. (2015). Nitroso-redox balance and modulation of basal myocardial function: An update from the italian society of cardiovascular research (SIRC). Current Drug Targets, 16(8), 895\u2013903. https:\/\/doi.org\/10.2174\/1389450116666150304103517","journal-title":"Current Drug Targets"},{"key":"9800_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811x-9-19","author":"S Patergnani","year":"2011","unstructured":"Patergnani, S., Suski, J. M., Agnoletto, C., Bononi, A., Bonora, M., De Marchi, E., Giorgi, C., Marchi, S., Missiroli, S., Poletti, F., Rimessi, A., Duszynski, J., Wieckowski, M. R., & Pinton, P. (2011). Calcium signaling around mitochondria associated membranes (MAMs). Cell Communication and Signaling\u202f: CCS,919. https:\/\/doi.org\/10.1186\/1478-811x-9-19","journal-title":"Cell Communication and Signaling : CCS,919"},{"issue":"1","key":"9800_CR57","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1042\/bst20110705","volume":"40","author":"ML Olson","year":"2012","unstructured":"Olson, M. L., Chalmers, S., & McCarron, J. G. (2012). Mitochondrial organization and Ca2+ uptake. Biochemical Society Transactions, 40(1), 158\u2013167. https:\/\/doi.org\/10.1042\/bst20110705","journal-title":"Biochemical Society Transactions"},{"issue":"5","key":"9800_CR58","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10495-017-1351-9","volume":"22","author":"Z Zhang","year":"2017","unstructured":"Zhang, Z., Zhao, L., Zhou, Y., Lu, X., Wang, Z., Wang, J., & Li, W. (2017). Taurine ameliorated homocysteine-induced H9C2 cardiomyocyte apoptosis by modulating endoplasmic reticulum stress. Apoptosis\u202f: An International Journal on Programmed Cell Death, 22(5), 647\u2013661. https:\/\/doi.org\/10.1007\/s10495-017-1351-9","journal-title":"Apoptosis : An International Journal on Programmed Cell Death"},{"issue":"3","key":"9800_CR59","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/hon.967","volume":"29","author":"MS Marcolino","year":"2011","unstructured":"Marcolino, M. S., Boersma, E., Clementino, N. C., Nunes, M. D., Barbosa, M. M., Silva, M. H., Geleijnse, M. L., & Ribeiro, A. L. (2011). The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid Leukaemia patients. Hematological Oncology, 29(3), 124\u2013130. https:\/\/doi.org\/10.1002\/hon.967","journal-title":"Hematological Oncology"},{"issue":"1","key":"9800_CR60","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ijcard.2009.07.006","volume":"145","author":"G Turrisi","year":"2010","unstructured":"Turrisi, G., Montagnani, F., Grotti, S., Marinozzi, C., Bolognese, L., & Fiorentini, G. (2010). Congestive heart failure during imatinib mesylate treatment. International Journal of Cardiology, 145(1), 148\u2013150. https:\/\/doi.org\/10.1016\/j.ijcard.2009.07.006","journal-title":"International Journal of Cardiology"},{"issue":"1","key":"9800_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajh.23330","volume":"88","author":"P Rousselot","year":"2013","unstructured":"Rousselot, P., Cony-Makhoul, P., Nicolini, F., Mahon, F. X., Berthou, C., R\u00e9a, D., Reiffers, J., Bornand, A., Saint-Jean, O., Guilhot, J., & Guilhot, F. (2013). Long-term safety and efficacy of imatinib mesylate (Gleevec\u00ae) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study. American Journal of Hematology, 88(1), 1\u20134. https:\/\/doi.org\/10.1002\/ajh.23330","journal-title":"American Journal of Hematology"},{"issue":"4","key":"9800_CR62","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1089\/thy.2010.0270","volume":"21","author":"ME Toubert","year":"2011","unstructured":"Toubert, M. E., Vercellino, L., Faugeron, I., Lussato, D., Hindie, E., & Bousquet, G. (2011). Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer. Thyroid: Official Journal of the American Thyroid Association, 21(4), 451\u2013454. https:\/\/doi.org\/10.1089\/thy.2010.0270","journal-title":"Thyroid: Official Journal of the American Thyroid Association"},{"key":"9800_CR63","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3389\/fphar.2020.01106","volume":"11","author":"J Bouitbir","year":"2020","unstructured":"Bouitbir, J., Panajatovic, M. V., Frechard, T., Roos, N. J., & Kr\u00e4henb\u00fchl, S. (2020). Imatinib and Dasatinib Provoke Mitochondrial Dysfunction Leading to Oxidative Stress in C2C12 Myotubes and Human RD Cells. Front Pharmacol, 11, 1106. https:\/\/doi.org\/10.3389\/fphar.2020.01106","journal-title":"Front Pharmacol"},{"key":"9800_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042282","author":"J Bouitbir","year":"2022","unstructured":"Bouitbir, J., Panajatovic, M. V., & Kr\u00e4henb\u00fchl, S. (2022). Mitochondrial Toxicity Associated with Imatinib and Sorafenib in Isolated Rat Heart Fibers and the Cardiomyoblast H9c2 Cell Line. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms23042282","journal-title":"International Journal of Molecular Sciences"},{"issue":"10","key":"9800_CR65","doi-asserted-by":"publisher","first-page":"7320","DOI":"10.1074\/jbc.M008363200","volume":"276","author":"EA Slee","year":"2001","unstructured":"Slee, E. A., Adrain, C., & Martin, S. J. (2001). Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. The Journal of Biological Chemistry, 276(10), 7320\u20137326. https:\/\/doi.org\/10.1074\/jbc.M008363200","journal-title":"The Journal of Biological Chemistry"},{"issue":"6828","key":"9800_CR66","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/35069004","volume":"410","author":"N Joza","year":"2001","unstructured":"Joza, N., Susin, S. A., Daugas, E., Stanford, W. L., Cho, S. K., Li, C. Y., Sasaki, T., Elia, A. J., Cheng, H. Y., Ravagnan, L., Ferri, K. F., Zamzami, N., Wakeham, A., Hakem, R., Yoshida, H., Kong, Y. Y., Mak, T. W., Z\u00fa\u00f1iga-Pfl\u00fccker, J. C., Kroemer, G., & Penninger, J. M. (2001). Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature, 410(6828), 549\u2013554. https:\/\/doi.org\/10.1038\/35069004","journal-title":"Nature"},{"issue":"3","key":"9800_CR67","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.yrtph.2013.09.002","volume":"67","author":"J Finsterer","year":"2013","unstructured":"Finsterer, J., & Ohnsorge, P. (2013). Influence of mitochondrion-toxic agents on the cardiovascular system. Regulatory Toxicology and Pharmacology: RTP, 67(3), 434\u2013445. https:\/\/doi.org\/10.1016\/j.yrtph.2013.09.002","journal-title":"Regulatory Toxicology and Pharmacology: RTP"},{"issue":"1","key":"9800_CR68","first-page":"188","volume":"62","author":"C Yu","year":"2002","unstructured":"Yu, C., Krystal, G., Varticovksi, L., McKinstry, R., Rahmani, M., Dent, P., & Grant, S. (2002). Pharmacologic mitogen-activated protein\/extracellular signal-regulated kinase kinase\/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr\/Abl-expressing human Leukemia cells. Cancer Research, 62(1), 188\u2013199.","journal-title":"Cancer Research"},{"issue":"2","key":"9800_CR69","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00018-002-8417-7","volume":"59","author":"M Thomson","year":"2002","unstructured":"Thomson, M. (2002). Evidence of undiscovered cell regulatory mechanisms: Phosphoproteins and protein kinases in mitochondria. Cellular and Molecular Life Sciences\u202f: CMLS, 59(2), 213\u2013219. https:\/\/doi.org\/10.1007\/s00018-002-8417-7","journal-title":"Cellular and Molecular Life Sciences : CMLS"},{"key":"9800_CR70","doi-asserted-by":"publisher","first-page":"630480","DOI":"10.3389\/fcvm.2020.630480","volume":"7","author":"CJ McMullen","year":"2020","unstructured":"McMullen, C. J., Chalmers, S., Wood, R., Cunningham, M. R., & Currie, S. (2020). Sunitinib and Imatinib display differential cardiotoxicity in adult rat cardiac fibroblasts that involves a role for calcium\/calmodulin dependent protein kinase II. Frontiers in Cardiovascular Medicine, 7, 630480. https:\/\/doi.org\/10.3389\/fcvm.2020.630480","journal-title":"Frontiers in Cardiovascular Medicine"},{"key":"9800_CR71","doi-asserted-by":"publisher","first-page":"115852","DOI":"10.1016\/j.taap.2021.115852","volume":"435","author":"C Song","year":"2022","unstructured":"Song, C., Li, D., Zhang, J., & Zhao, X. (2022). Role of ferroptosis in promoting cardiotoxicity induced by Imatinib Mesylate via down-regulating Nrf2 pathways in vitro and in vivo. Toxicology and Applied Pharmacology, 435, 115852. https:\/\/doi.org\/10.1016\/j.taap.2021.115852","journal-title":"Toxicology and Applied Pharmacology"},{"key":"9800_CR72","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijcard.2020.05.077","volume":"316","author":"AP Singh","year":"2020","unstructured":"Singh, A. P., Umbarkar, P., Tousif, S., & Lal, H. (2020). Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib. International Journal of Cardiology, 316, 214\u2013221. https:\/\/doi.org\/10.1016\/j.ijcard.2020.05.077","journal-title":"International Journal of Cardiology"},{"issue":"S4","key":"9800_CR73","doi-asserted-by":"publisher","first-page":"53","DOI":"10.18087\/cardio.2428","volume":"57","author":"LM Makeeva","year":"2017","unstructured":"Makeeva, L. M., Emelina, E. I., Gendlin, G. E., Nikitin, I. G., Vasyuk, Y. A., & Nesvetov, V. V. (2017). Pulmonary arterial hypertension and chronic heart failure as dasatinib cardiotoxicity. A case report. Kardiologiia, 57(S4), 53\u201360.","journal-title":"Kardiologiia"},{"issue":"1","key":"9800_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1253\/circrep.CR-21-0140","volume":"4","author":"T Motokawa","year":"2022","unstructured":"Motokawa, T., Ikeda, S., Ueno, Y., Eguchi, M., Minami, T., Kawano, H., Kobayashi, K., Imaizumi, Y., & Maemura, K. (2022). Comparison of dasatinib- and imatinib-related cardiotoxic adverse events in Japanese patients with chronic myeloid Leukemia and gastrointestinal stromal tumor. Circulation Reports, 4(1), 1\u20138. https:\/\/doi.org\/10.1253\/circrep.CR-21-0140","journal-title":"Circulation Reports"},{"issue":"9","key":"9800_CR75","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1172\/jci86249","volume":"126","author":"C Guignabert","year":"2016","unstructured":"Guignabert, C., Phan, C., Seferian, A., Huertas, A., Tu, L., Thuillet, R., Sattler, C., Le Hiress, M., Tamura, Y., Jutant, E. M., Chaumais, M. C., Bouchet, S., Man\u00e9glier, B., Molimard, M., Rousselot, P., Sitbon, O., Simonneau, G., Montani, D., & Humbert, M. (2016). Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. The Journal of Clinical Investigation, 126(9), 3207\u20133218. https:\/\/doi.org\/10.1172\/jci86249","journal-title":"The Journal of Clinical Investigation"},{"issue":"2","key":"9800_CR76","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D. W., Issaragrisil, S., le Coutre, P., Etienne, G., Boquimpani, C., Pasquini, R., Clark, R. E., Dubruille, V., Flinn, I. W., Kyrcz-Krzemien, S., Medras, E., Zanichelli, M., Bendit, I., Cacciatore, S., Titorenko, K., Aimone, P., \u2026 Hochhaus, A. (2021). Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia, 35(2), 440\u2013453. https:\/\/doi.org\/10.1038\/s41375-020-01111-2","journal-title":"Leukemia"},{"issue":"7","key":"9800_CR77","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ajh.22037","volume":"86","author":"KJ Aichberger","year":"2011","unstructured":"Aichberger, K. J., Herndlhofer, S., Schernthaner, G. H., Schillinger, M., Mitterbauer-Hohendanner, G., Sillaber, C., & Valent, P. (2011). Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. American Journal of Hematology, 86(7), 533\u2013539. https:\/\/doi.org\/10.1002\/ajh.22037","journal-title":"American Journal of Hematology"},{"issue":"11","key":"9800_CR78","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1038\/leu.2017.245","volume":"31","author":"E Hadzijusufovic","year":"2017","unstructured":"Hadzijusufovic, E., Albrecht-Schgoer, K., Huber, K., Hoermann, G., Grebien, F., Eisenwort, G., Schgoer, W., Herndlhofer, S., Kaun, C., Theurl, M., Sperr, W. R., Rix, U., Sadovnik, I., Jilma, B., Schernthaner, G. H., Wojta, J., Wolf, D., Superti-Furga, G., Kirchmair, R., & Valent, P. (2017). Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia, 31(11), 2388\u20132397. https:\/\/doi.org\/10.1038\/leu.2017.245","journal-title":"Leukemia"},{"issue":"9","key":"9800_CR79","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","volume":"123","author":"HM Kantarjian","year":"2014","unstructured":"Kantarjian, H. M., Cortes, J. E., Kim, D. W., Khoury, H. J., Br\u00fcmmendorf, T. H., Porkka, K., Martinelli, G., Durrant, S., Leip, E., Kelly, V., Turnbull, K., Besson, N., & Gambacorti-Passerini, C. (2014). Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood, 123(9), 1309\u20131318. https:\/\/doi.org\/10.1182\/blood-2013-07-513937","journal-title":"Blood"},{"issue":"4","key":"9800_CR80","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s12012-020-09565-7","volume":"20","author":"BB Hasinoff","year":"2020","unstructured":"Hasinoff, B. B., & Patel, D. (2020). Mechanisms of the cardiac myocyte-damaging effects of dasatinib. Cardiovascular Toxicology, 20(4), 380\u2013389. https:\/\/doi.org\/10.1007\/s12012-020-09565-7","journal-title":"Cardiovascular Toxicology"},{"issue":"Suppl 4","key":"9800_CR81","doi-asserted-by":"publisher","first-page":"505","DOI":"10.33549\/physiolres.933504","volume":"65","author":"D Lekes","year":"2016","unstructured":"Lekes, D., Szadvari, I., Krizanova, O., Lopusna, K., Rezuchova, I., Novakova, M., Novakova, Z., Parak, T., & Babula, P. (2016). Nilotinib induces ER stress and cell death in H9c2 cells. Physiological Research, 65(Suppl 4), 505\u2013514. https:\/\/doi.org\/10.33549\/physiolres.933504","journal-title":"Physiological Research"},{"issue":"3","key":"9800_CR82","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/bloodadvances.2019000268","volume":"4","author":"O Chan","year":"2020","unstructured":"Chan, O., Talati, C., Isenalumhe, L., Shams, S., Nodzon, L., Fradley, M., Sweet, K., & Pinilla-Ibarz, J. (2020). Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood Advances, 4(3), 530\u2013538. https:\/\/doi.org\/10.1182\/bloodadvances.2019000268","journal-title":"Blood Advances"},{"issue":"1","key":"9800_CR83","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/toxsci\/kfu215","volume":"143","author":"DR Talbert","year":"2015","unstructured":"Talbert, D. R., Doherty, K. R., Trusk, P. B., Moran, D. M., Shell, S. A., & Bacus, S. (2015). A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity. Toxicological Sciences: An Official Journal of the Society of Toxicology, 143(1), 147\u2013155. https:\/\/doi.org\/10.1093\/toxsci\/kfu215","journal-title":"Toxicological Sciences: An Official Journal of the Society of Toxicology"},{"key":"9800_CR84","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.tox.2018.01.005","volume":"395","author":"F Paech","year":"2018","unstructured":"Paech, F., Mingard, C., Gr\u00fcnig, D., Abegg, V. F., Bouitbir, J., & Kr\u00e4henb\u00fchl, S. (2018). Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells. Toxicology, 395, 34\u201344. https:\/\/doi.org\/10.1016\/j.tox.2018.01.005","journal-title":"Toxicology"},{"issue":"24","key":"9800_CR85","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes, T. P., Mauro, M. J., Cortes, J. E., Minami, H., Rea, D., DeAngelo, D. J., Breccia, M., Goh, Y.-T., Talpaz, M., Hochhaus, A., le Coutre, P., Ottmann, O., Heinrich, M. C., Steegmann, J. L., Deininger, M. W. N., Janssen, J. J. W. M., Mahon, F.-X., Minami, Y., Yeung, D., \u2026 Kim, D.-W. (2019). Asciminib in chronic myeloid Leukemia after ABL kinase inhibitor failure. The New England Journal of Medicine, 381(24), 2315\u20132326. https:\/\/doi.org\/10.1056\/NEJMoa1902328","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"9800_CR86","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.tem.2014.06.007","volume":"25","author":"TK Rainbolt","year":"2014","unstructured":"Rainbolt, T. K., Saunders, J. M., & Wiseman, R. L. (2014). Stress-responsive regulation of mitochondria through the ER unfolded protein response. Trends in endocrinology and metabolism: TEM, 25(10), 528\u2013537. https:\/\/doi.org\/10.1016\/j.tem.2014.06.007","journal-title":"Trends in endocrinology and metabolism: TEM"},{"key":"9800_CR87","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3120539","author":"P Gao","year":"2020","unstructured":"Gao, P., Yang, W., & Sun, L. (2020). Mitochondria-associated endoplasmic reticulum membranes (MAMs) and their prospective roles in kidney disease. Oxidative Medicine and Cellular Longevity. https:\/\/doi.org\/10.1155\/2020\/3120539","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"9","key":"9800_CR88","doi-asserted-by":"publisher","first-page":"a004424","DOI":"10.1101\/cshperspect.a004424","volume":"3","author":"JD Malhotra","year":"2011","unstructured":"Malhotra, J. D., & Kaufman, R. J. (2011). ER stress and its functional link to mitochondria: role in cell survival and death. Cold Spring Harbor Perspectives in Biology, 3(9), a004424. https:\/\/doi.org\/10.1101\/cshperspect.a004424","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"Pt 2","key":"9800_CR89","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1113\/jphysiol.2003.049478","volume":"552","author":"JF Turrens","year":"2003","unstructured":"Turrens, J. F. (2003). Mitochondrial formation of reactive oxygen species. The Journal of Physiology, 552(Pt 2), 335\u2013344. https:\/\/doi.org\/10.1113\/jphysiol.2003.049478","journal-title":"The Journal of Physiology"},{"key":"9800_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030520","author":"C Rocca","year":"2022","unstructured":"Rocca, C., De Francesco, E. M., Pasqua, T., Granieri, M. C., De Bartolo, A., Gallo Cantafio, M. E., Muoio, M. G., Gentile, M., Neri, A., Angelone, T., Viglietto, G., & Amodio, N. (2022). Mitochondrial determinants of anti-cancer drug-induced cardiotoxicity. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10030520","journal-title":"Biomedicines"},{"key":"9800_CR91","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1475-2840-12-158","volume":"12","author":"ZW Liu","year":"2013","unstructured":"Liu, Z. W., Zhu, H. T., Chen, K. L., Dong, X., Wei, J., Qiu, C., & Xue, J. H. (2013). Protein kinase RNA-like endoplasmic reticulum kinase (PERK) signaling pathway plays a major role in reactive oxygen species (ROS)-mediated endoplasmic reticulum stress-induced apoptosis in diabetic cardiomyopathy. Cardiovascular Diabetology, 12, 158. https:\/\/doi.org\/10.1186\/1475-2840-12-158","journal-title":"Cardiovascular Diabetology"},{"issue":"18","key":"9800_CR92","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.1128\/mcb.21.18.6233-6242.2001","volume":"21","author":"Y Ito","year":"2001","unstructured":"Ito, Y., Pandey, P., Mishra, N., Kumar, S., Narula, N., Kharbanda, S., Saxena, S., & Kufe, D. (2001). Targeting of the c-Abl tyrosine kinase to mitochondria in endoplasmic reticulum stress-induced apoptosis. Molecular and Cellular Biology, 21(18), 6233\u20136242. https:\/\/doi.org\/10.1128\/mcb.21.18.6233-6242.2001","journal-title":"Molecular and Cellular Biology"},{"issue":"2","key":"9800_CR93","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/s0145-2126(03)00218-2","volume":"28","author":"L Pattacini","year":"2004","unstructured":"Pattacini, L., Mancini, M., Mazzacurati, L., Brusa, G., Benvenuti, M., Martinelli, G., Baccarani, M., & Santucci, M. A. (2004). Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr-abl tyrosine kinase. Leukemia Research, 28(2), 191\u2013202. https:\/\/doi.org\/10.1016\/s0145-2126(03)00218-2","journal-title":"Leukemia Research"},{"issue":"25","key":"9800_CR94","doi-asserted-by":"publisher","first-page":"25935","DOI":"10.1074\/jbc.R400008200","volume":"279","author":"K Zhang","year":"2004","unstructured":"Zhang, K., & Kaufman, R. J. (2004). Signaling the unfolded protein response from the endoplasmic reticulum. The Journal of Biological Chemistry, 279(25), 25935\u201325938. https:\/\/doi.org\/10.1074\/jbc.R400008200","journal-title":"The Journal of Biological Chemistry"},{"key":"9800_CR95","doi-asserted-by":"publisher","first-page":"102474","DOI":"10.1016\/j.redox.2022.102474","volume":"57","author":"A Lozhkin","year":"2022","unstructured":"Lozhkin, A., Vendrov, A. E., Ramos-Mondrag\u00f3n, R., Canugovi, C., Stevenson, M. D., Herron, T. J., Hummel, S. L., Figueroa, C. A., Bowles, D. E., Isom, L. L., Runge, M. S., & Madamanchi, N. R. (2022). Mitochondrial oxidative stress contributes to diastolic dysfunction through impaired mitochondrial dynamics. Redox Biology, 57, 102474. https:\/\/doi.org\/10.1016\/j.redox.2022.102474","journal-title":"Redox Biology"},{"key":"9800_CR96","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-3573-0_6","author":"S Dr\u00f6se","year":"2012","unstructured":"Dr\u00f6se, S., & Brandt, U. (2012). Molecular mechanisms of superoxide production by the mitochondrial respiratory chain. Advances in Experimental Medicine and Biology. https:\/\/doi.org\/10.1007\/978-1-4614-3573-0_6","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"6","key":"9800_CR97","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/j.1745-7254.2008.00794.x","volume":"29","author":"P Liu","year":"2008","unstructured":"Liu, P., Xiang, J. Z., Zhao, L., Yang, L., Hu, B. R., & Fu, Q. (2008). Effect of beta2-adrenergic agonist clenbuterol on ischemia\/reperfusion injury in isolated rat hearts and cardiomyocyte apoptosis induced by hydrogen peroxide. Acta Pharmacologica Sinica, 29(6), 661\u2013669. https:\/\/doi.org\/10.1111\/j.1745-7254.2008.00794.x","journal-title":"Acta Pharmacologica Sinica"},{"issue":"1","key":"9800_CR98","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1038\/s41467-018-06533-2","volume":"9","author":"B Steinhorn","year":"2018","unstructured":"Steinhorn, B., Sorrentino, A., Badole, S., Bogdanova, Y., Belousov, V., & Michel, T. (2018). Chemogenetic generation of hydrogen peroxide in the heart induces severe cardiac dysfunction. Nature Communications, 9(1), 4044. https:\/\/doi.org\/10.1038\/s41467-018-06533-2","journal-title":"Nature Communications"},{"key":"9800_CR99","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00279-2020","author":"J Weatherald","year":"2020","unstructured":"Weatherald, J., Bondeelle, L., Chaumais, M. C., Guignabert, C., Savale, L., Ja\u00efs, X., Sitbon, O., Rousselot, P., Humbert, M., Bergeron, A., & Montani, D. (2020). Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. The European Respiratory Journal. https:\/\/doi.org\/10.1183\/13993003.00279-2020","journal-title":"The European Respiratory Journal"},{"issue":"6","key":"9800_CR100","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1002\/jcb.26686","volume":"119","author":"S Damiano","year":"2018","unstructured":"Damiano, S., Montagnaro, S., Puzio, M. V., Severino, L., Pagnini, U., Barbarino, M., Cesari, D., Giordano, A., Florio, S., & Ciarcia, R. (2018). Effects of antioxidants on apoptosis induced by dasatinib and nilotinib in K562 cells. Journal of Cellular Biochemistry, 119(6), 4845\u20134854. https:\/\/doi.org\/10.1002\/jcb.26686","journal-title":"Journal of Cellular Biochemistry"},{"issue":"1","key":"9800_CR101","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0003-9861(66)90036-1","volume":"116","author":"DE Green","year":"1966","unstructured":"Green, D. E., & Tzagoloff, A. (1966). The mitochondrial electron transfer chain. Archives of Biochemistry and Biophysics, 116(1), 293\u2013304. https:\/\/doi.org\/10.1016\/0003-9861(66)90036-1","journal-title":"Archives of Biochemistry and Biophysics"},{"issue":"38","key":"9800_CR102","doi-asserted-by":"publisher","first-page":"36027","DOI":"10.1074\/jbc.M304854200","volume":"278","author":"Q Chen","year":"2003","unstructured":"Chen, Q., Vazquez, E. J., Moghaddas, S., Hoppel, C. L., & Lesnefsky, E. J. (2003). Production of reactive oxygen species by mitochondria: Central role of complex III. The Journal of Biological Chemistry, 278(38), 36027\u201336031. https:\/\/doi.org\/10.1074\/jbc.M304854200","journal-title":"The Journal of Biological Chemistry"},{"issue":"6","key":"9800_CR103","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1111\/brv.12764","volume":"96","author":"G Morciano","year":"2021","unstructured":"Morciano, G., Naumova, N., Koprowski, P., Valente, S., Sard\u00e3o, V. A., Potes, Y., Rimessi, A., Wieckowski, M. R., & Oliveira, P. J. (2021). The mitochondrial permeability transition pore: An evolving concept critical for cell life and death. Biological Reviews of the Cambridge Philosophical Society, 96(6), 2489\u20132521. https:\/\/doi.org\/10.1111\/brv.12764","journal-title":"Biological Reviews of the Cambridge Philosophical Society"},{"issue":"2","key":"9800_CR104","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.cmet.2014.12.001","volume":"21","author":"JQ Kwong","year":"2015","unstructured":"Kwong, J. Q., & Molkentin, J. D. (2015). Physiological and pathological roles of the mitochondrial permeability transition pore in the heart. Cell Metabolism, 21(2), 206\u2013214. https:\/\/doi.org\/10.1016\/j.cmet.2014.12.001","journal-title":"Cell Metabolism"},{"issue":"4","key":"9800_CR105","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/s0092-8674(00)80434-1","volume":"91","author":"P Li","year":"1997","unstructured":"Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & Wang, X. (1997). Cytochrome c and dATP-dependent formation of Apaf-1\/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91(4), 479\u2013489. https:\/\/doi.org\/10.1016\/s0092-8674(00)80434-1","journal-title":"Cell"},{"issue":"6","key":"9800_CR106","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1159\/000479993","volume":"42","author":"Q Yang","year":"2017","unstructured":"Yang, Q., Zhang, C., Wei, H., Meng, Z., Li, G., Xu, Y., & Chen, Y. (2017). Caspase-independent pathway is related to nilotinib cytotoxicity in cultured cardiomyocytes. Cellular Physiology and Biochemistry\u202f: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 42(6), 2182\u20132193. https:\/\/doi.org\/10.1159\/000479993","journal-title":"Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology"},{"issue":"2","key":"9800_CR107","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/s0092-8674(00)00116-1","volume":"103","author":"RJ Davis","year":"2000","unstructured":"Davis, R. J. (2000). Signal transduction by the JNK group of MAP kinases. Cell, 103(2), 239\u2013252. https:\/\/doi.org\/10.1016\/s0092-8674(00)00116-1","journal-title":"Cell"},{"issue":"5453","key":"9800_CR108","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1126\/science.287.5453.664","volume":"287","author":"F Urano","year":"2000","unstructured":"Urano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P., Harding, H. P., & Ron, D. (2000). Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science (New York, N.Y.), 287(5453), 664\u2013666. https:\/\/doi.org\/10.1126\/science.287.5453.664","journal-title":"Science (New York, N.Y.)"},{"issue":"18","key":"9800_CR109","doi-asserted-by":"publisher","first-page":"16052","DOI":"10.1074\/jbc.M111.223602","volume":"286","author":"JW Chambers","year":"2011","unstructured":"Chambers, J. W., & LoGrasso, P. V. (2011). Mitochondrial c-Jun N-terminal kinase (JNK) signaling initiates physiological changes resulting in amplification of reactive oxygen species generation. The Journal of Biological Chemistry, 286(18), 16052\u201316062. https:\/\/doi.org\/10.1074\/jbc.M111.223602","journal-title":"The Journal of Biological Chemistry"},{"key":"9800_CR110","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejphar.2018.01.011","volume":"822","author":"Q Yang","year":"2018","unstructured":"Yang, Q., Wen, L., Meng, Z., & Chen, Y. (2018). Blockage of endoplasmic reticulum stress attenuates nilotinib-induced cardiotoxicity by inhibition of the Akt-GSK3\u03b2-Nox4 signaling. European Journal of Pharmacology, 822, 85\u201394. https:\/\/doi.org\/10.1016\/j.ejphar.2018.01.011","journal-title":"European Journal of Pharmacology"},{"key":"9800_CR111","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.tox.2017.03.006","volume":"382","author":"TP Chambers","year":"2017","unstructured":"Chambers, T. P., Santiesteban, L., Gomez, D., & Chambers, J. W. (2017). Sab mediates mitochondrial dysfunction involved in imatinib mesylate-induced cardiotoxicity. Toxicology, 382, 24\u201335. https:\/\/doi.org\/10.1016\/j.tox.2017.03.006","journal-title":"Toxicology"},{"key":"9800_CR112","doi-asserted-by":"publisher","first-page":"6227","DOI":"10.2147\/ott.S170138","volume":"11","author":"M Chaar","year":"2018","unstructured":"Chaar, M., Kamta, J., & Ait-Oudhia, S. (2018). Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities. OncoTargets and Therapy, 11, 6227\u20136237. https:\/\/doi.org\/10.2147\/ott.S170138","journal-title":"OncoTargets and Therapy"},{"issue":"11","key":"9800_CR113","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1182\/blood.V110.11.4582.4582","volume":"110","author":"WJ Freebern","year":"2007","unstructured":"Freebern, W. J., Fang, H. S., Slade, M. D., Wells, S., Canale, J., Megill, J., Grubor, B., Shi, H., Fletcher, A., Lombardo, L., Levesque, P., Lee, F. Y., & Sasseville, V. G. (2007). In vitro cardiotoxicity potential comparative assessments of chronic myelogenous leukemia tyrosine kinase inhibitor therapies: Dasatinib imatinib and nilotinib. Blood, 110(11), 4582. https:\/\/doi.org\/10.1182\/blood.V110.11.4582.4582","journal-title":"Blood"},{"issue":"9","key":"9800_CR114","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.leukres.2010.01.004","volume":"34","author":"A Wolf","year":"2010","unstructured":"Wolf, A., Couttet, P., Dong, M., Grenet, O., Heron, M., Junker, U., Laengle, U., Ledieu, D., Marrer, E., Nussher, A., Persohn, E., Pognan, F., Rivi\u00e8re, G. J., Roth, D. R., Trendelenburg, C., Tsao, J., & Roman, D. (2010). Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leukemia Research, 34(9), 1180\u20131188. https:\/\/doi.org\/10.1016\/j.leukres.2010.01.004","journal-title":"Leukemia Research"},{"issue":"3","key":"9800_CR115","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s12012-016-9386-7","volume":"17","author":"BB Hasinoff","year":"2017","unstructured":"Hasinoff, B. B., Patel, D., & Wu, X. (2017). The myocyte-damaging effects of the BCR-ABL1-targeted tyrosine kinase inhibitors increase with potency and decrease with specificity. Cardiovascular Toxicology, 17(3), 297\u2013306. https:\/\/doi.org\/10.1007\/s12012-016-9386-7","journal-title":"Cardiovascular Toxicology"},{"issue":"6","key":"9800_CR116","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1096\/fj.05-5426fje","volume":"20","author":"S Kobayashi","year":"2006","unstructured":"Kobayashi, S., Lackey, T., Huang, Y., Bisping, E., Pu, W. T., Boxer, L. M., & Liang, Q. (2006). Transcription factor gata4 regulates cardiac BCL2 gene expression in vitro and in vivo. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 20(6), 800\u2013802. https:\/\/doi.org\/10.1096\/fj.05-5426fje","journal-title":"FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology"},{"issue":"1\u20132","key":"9800_CR117","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11010-012-1252-8","volume":"365","author":"Z Sarszegi","year":"2012","unstructured":"Sarszegi, Z., Bognar, E., Gaszner, B., K\u00f3nyi, A., Gallyas, F., Jr., Sumegi, B., & Berente, Z. (2012). BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Molecular and Cellular Biochemistry, 365(1\u20132), 129\u2013137. https:\/\/doi.org\/10.1007\/s11010-012-1252-8","journal-title":"Molecular and Cellular Biochemistry"},{"key":"9800_CR118","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.toxlet.2018.08.003","volume":"296","author":"Z Xu","year":"2018","unstructured":"Xu, Z., Jin, Y., Yan, H., Gao, Z., Xu, B., Yang, B., He, Q., Shi, Q., & Luo, P. (2018). High-mobility group box 1 protein-mediated necroptosis contributes to dasatinib-induced cardiotoxicity. Toxicology Letters, 296, 39\u201347. https:\/\/doi.org\/10.1016\/j.toxlet.2018.08.003","journal-title":"Toxicology Letters"},{"issue":"9","key":"9800_CR119","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1080\/15376516.2018.1497746","volume":"28","author":"AMS Alsaad","year":"2018","unstructured":"Alsaad, A. M. S. (2018). Dasatinib induces gene expression of CYP1A1, CYP1B1, and cardiac hypertrophy markers (BNP, \u03b2-MHC) in rat cardiomyocyte H9c2 cells. Toxicology Mechanisms and Methods, 28(9), 678\u2013684. https:\/\/doi.org\/10.1080\/15376516.2018.1497746","journal-title":"Toxicology Mechanisms and Methods"},{"issue":"5","key":"9800_CR120","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1111\/jcmm.17008","volume":"26","author":"R Madonna","year":"2022","unstructured":"Madonna, R., Pieragostino, D., Cufaro, M. C., Del Boccio, P., Pucci, A., Mattii, L., Doria, V., Cadeddu Dessalvi, C., Zucchi, R., Mercuro, G., & De Caterina, R. (2022). Sex-related differential susceptibility to ponatinib cardiotoxicity and differential modulation of the Notch1 signalling pathway in a murine model. Journal of Cellular and Molecular Medicine, 26(5), 1380\u20131391. https:\/\/doi.org\/10.1111\/jcmm.17008","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"5","key":"9800_CR121","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/cvr\/cvz006","volume":"115","author":"AP Singh","year":"2019","unstructured":"Singh, A. P., Glennon, M. S., Umbarkar, P., Gupte, M., Galindo, C. L., Zhang, Q., Force, T., Becker, J. R., & Lal, H. (2019). Ponatinib-induced cardiotoxicity: Delineating the signalling mechanisms and potential rescue strategies. Cardiovascular Research, 115(5), 966\u2013977. https:\/\/doi.org\/10.1093\/cvr\/cvz006","journal-title":"Cardiovascular Research"},{"key":"9800_CR122","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2584","author":"A Sharma","year":"2017","unstructured":"Sharma, A., Burridge, P. W., McKeithan, W. L., Serrano, R., Shukla, P., Sayed, N., Churko, J. M., Kitani, T., Wu, H. D., Holmstrom, A., Matsa, E., Zhang, Y., Kumar, A., Fan, A. C., del Alamo, J. C., Wu, S. M., Moslehi, J. J., Mercola, M., & Wu, J. C. (2017). High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Science Translational Medicine. https:\/\/doi.org\/10.1126\/scitranslmed.aaf2584","journal-title":"Science Translational Medicine"},{"issue":"14","key":"9800_CR123","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","volume":"133","author":"Y Latifi","year":"2019","unstructured":"Latifi, Y., Moccetti, F., Wu, M., Xie, A., Packwood, W., Qi, Y., Ozawa, K., Shentu, W. H., Brown, E., Shirai, T., McCarty, O. J., Ruggeri, Z., Moslehi, J., Chen, J. M., Druker, B. J., Lopez, J. A., & Lindner, J. R. (2019). Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood, 133(14), 1597\u20131606. https:\/\/doi.org\/10.1182\/blood-2018-10-881557","journal-title":"Blood"},{"issue":"22","key":"9800_CR124","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1182\/blood.V128.22.1883.1883","volume":"128","author":"E Hadzijusufovic","year":"2016","unstructured":"Hadzijusufovic, E., Kirchmair, R., Theurl, M., Gamperl, S., Lener, D., Gutmann, C., Stanzl, U., Kirsch, A., Frank, S., & Valent, P. (2016). Ponatinib exerts multiple effects on vascular endothelial cells: Possible mechanisms and explanations for the adverse vascular events seen in CML patients treated with ponatinib. Blood, 128(22), 1883. https:\/\/doi.org\/10.1182\/blood.V128.22.1883.1883","journal-title":"Blood"},{"key":"9800_CR125","doi-asserted-by":"publisher","DOI":"10.1111\/micc.12625","author":"MJ Durand","year":"2020","unstructured":"Durand, M. J., Hader, S. N., Derayunan, A., Zinkevich, N., McIntosh, J. J., & Beyer, A. M. (2020). BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature. Microcirculation. https:\/\/doi.org\/10.1111\/micc.12625","journal-title":"Microcirculation"},{"issue":"10","key":"9800_CR126","first-page":"1530","volume":"51","author":"SB Zhou","year":"2016","unstructured":"Zhou, S. B., Wang, J., & Liu, H. (2016). Lead compound optimization strategy(5) \u2013 reducing the hERG cardiac toxicity in drug development. Yao xue xue bao = Acta pharmaceutica Sinica, 51(10), 1530\u20131539.","journal-title":"Yao xue xue bao = Acta pharmaceutica Sinica"},{"issue":"1","key":"9800_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12012-009-9056-0","volume":"10","author":"BB Hasinoff","year":"2010","unstructured":"Hasinoff, B. B., & Patel, D. (2010). Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib. Cardiovascular Toxicology, 10(1), 1\u20138. https:\/\/doi.org\/10.1007\/s12012-009-9056-0","journal-title":"Cardiovascular Toxicology"},{"key":"9800_CR128","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/vhrm.S108874","volume":"13","author":"N Aghel","year":"2017","unstructured":"Aghel, N., Delgado, D. H., & Lipton, J. H. (2017). Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: Preventive strategies and cardiovascular surveillance. Vascular Health and Risk Management, 13, 293\u2013303. https:\/\/doi.org\/10.2147\/vhrm.S108874","journal-title":"Vascular Health and Risk Management"},{"issue":"5","key":"9800_CR129","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/bcp.13508","volume":"84","author":"N \u00d6zg\u00fcr Yurtta\u015f","year":"2018","unstructured":"\u00d6zg\u00fcr Yurtta\u015f, N., & E\u015fkazan, A. E. (2018). Dasatinib-induced pulmonary arterial hypertension. British Journal of Clinical Pharmacology, 84(5), 835\u2013845. https:\/\/doi.org\/10.1111\/bcp.13508","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"10","key":"9800_CR130","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","volume":"4","author":"EK Oikonomou","year":"2019","unstructured":"Oikonomou, E. K., Kokkinidis, D. G., Kampaktsis, P. N., Amir, E. A., Marwick, T. H., Gupta, D., & Thavendiranathan, P. (2019). Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: A systematic review and meta-analysis. JAMA Cardiology, 4(10), 1007\u20131018. https:\/\/doi.org\/10.1001\/jamacardio.2019.2952","journal-title":"JAMA Cardiology"},{"issue":"7","key":"9800_CR131","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000505486","volume":"98","author":"G Novo","year":"2020","unstructured":"Novo, G., Di Lisi, D., Bronte, E., Macaione, F., Accurso, V., Badalamenti, G., Rinaldi, G., Siragusa, S., Novo, S., & Russo, A. (2020). Cardiovascular toxicity in cancer patients treated with tyrosine kinase inhibitors: A real-world single-center experience. Oncology, 98(7), 445\u2013451. https:\/\/doi.org\/10.1159\/000505486","journal-title":"Oncology"},{"issue":"4","key":"9800_CR132","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan, P., Negishi, T., Somerset, E., Negishi, K., Penicka, M., Lemieux, J., Aakhus, S., Miyazaki, S., Shirazi, M., Galderisi, M., & Marwick, T. H. (2021). Strain-guided management of potentially cardiotoxic cancer therapy. Journal of the American College of Cardiology, 77(4), 392\u2013401. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.020","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"9800_CR133","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00277-016-2820-x","volume":"96","author":"M Breccia","year":"2017","unstructured":"Breccia, M., Pregno, P., Spallarossa, P., Arboscello, E., Ciceri, F., Giorgi, M., Grossi, A., Mallardo, M., Nodari, S., Ottolini, S., Sala, C., Tortorella, G., Rosti, G., Pane, F., Minotti, G., & Baccarani, M. (2017). Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: An expert opinion. Annals of Hematology, 96(4), 549\u2013558. https:\/\/doi.org\/10.1007\/s00277-016-2820-x","journal-title":"Annals of Hematology"},{"issue":"3","key":"9800_CR134","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hon.2606","volume":"37","author":"G Caocci","year":"2019","unstructured":"Caocci, G., Mulas, O., Abruzzese, E., Luciano, L., Iurlo, A., Attolico, I., Castagnetti, F., Galimberti, S., Sgherza, N., Bonifacio, M., Annunziata, M., Gozzini, A., Orlandi, E. M., Stagno, F., Binotto, G., Pregno, P., Fozza, C., Trawinska, M. M., De Gregorio, F., \u2026 Breccia, M. (2019). Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Hematological Oncology, 37(3), 296\u2013302. https:\/\/doi.org\/10.1002\/hon.2606","journal-title":"Hematological Oncology"},{"issue":"8","key":"9800_CR135","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s00277-020-04392-w","volume":"100","author":"G Caocci","year":"2021","unstructured":"Caocci, G., Mulas, O., Capodanno, I., Bonifacio, M., Annunziata, M., Galimberti, S., Luciano, L., Tiribelli, M., Martino, B., Castagnetti, F., Binotto, G., Pregno, P., Stagno, F., Abruzzese, E., Bocchia, M., Gozzini, A., Albano, F., Fozza, C., Luzi, D., \u2026 La Nasa, G. (2021). Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. Annals of Hematology, 100(8), 2005\u20132014. https:\/\/doi.org\/10.1007\/s00277-020-04392-w","journal-title":"Annals of Hematology"},{"issue":"3","key":"9800_CR136","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/ehf2.13897","volume":"9","author":"D Di Lisi","year":"2022","unstructured":"Di Lisi, D., Madaudo, C., Alagna, G., Santoro, M., Rossetto, L., Siragusa, S., & Novo, G. (2022). The new HFA\/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity. ESC Heart Failure, 9(3), 1914\u20131919. https:\/\/doi.org\/10.1002\/ehf2.13897","journal-title":"ESC Heart Failure"},{"issue":"12","key":"9800_CR137","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1172\/jci32373","volume":"117","author":"A Fern\u00e1ndez","year":"2007","unstructured":"Fern\u00e1ndez, A., Sanguino, A., Peng, Z., Ozturk, E., Chen, J., Crespo, A., Wulf, S., Shavrin, A., Qin, C., Ma, J., Trent, J., Lin, Y., Han, H. D., Mangala, L. S., Bankson, J. A., Gelovani, J., Samarel, A., Bornmann, W., Sood, A. K., & Lopez-Berestein, G. (2007). An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. The Journal of Clinical Investigation, 117(12), 4044\u20134054. https:\/\/doi.org\/10.1172\/jci32373","journal-title":"The Journal of Clinical Investigation"},{"issue":"12","key":"9800_CR138","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1172\/jci34252","volume":"117","author":"GD Demetri","year":"2007","unstructured":"Demetri, G. D. (2007). Structural reengineering of imatinib to decrease cardiac risk in cancer therapy. Journal of Clinical Investigation, 117(12), 3650\u20133653. https:\/\/doi.org\/10.1172\/jci34252","journal-title":"Journal of Clinical Investigation"},{"issue":"15","key":"9800_CR139","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1158\/0008-5472.CAN-21-3652","volume":"82","author":"AP Hnatiuk","year":"2022","unstructured":"Hnatiuk, A. P., Bruyneel, A. A. N., Tailor, D., Pandrala, M., Dheeraj, A., Li, W., Serrano, R., Feyen, D. A. M., Vu, M. M., Amatya, P., Gupta, S., Nakauchi, Y., Morgado, I., Wiebking, V., Liao, R., Porteus, M. H., Majeti, R., Malhotra, S. V., & Mercola, M. (2022). Reengineering Ponatinib to Minimize Cardiovascular Toxicity. Cancer Research, 82(15), 2777\u20132791. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-3652","journal-title":"Cancer Research"},{"key":"9800_CR140","doi-asserted-by":"publisher","first-page":"118124","DOI":"10.1016\/j.lfs.2020.118124","volume":"258","author":"Y Guo","year":"2020","unstructured":"Guo, Y., Wang, X., Jia, P., You, Y., Cheng, Y., Deng, H., Luo, S., & Huang, B. (2020). Ketogenic diet aggravates hypertension via NF-\u03baB-mediated endothelial dysfunction in spontaneously hypertensive rats. Life Sci, 258, 118124. https:\/\/doi.org\/10.1016\/j.lfs.2020.118124","journal-title":"Life Sci"},{"key":"9800_CR141","doi-asserted-by":"publisher","first-page":"106050","DOI":"10.1016\/j.biocel.2021.106050","volume":"138","author":"C Qu","year":"2021","unstructured":"Qu, C., Keijer, J., Adjobo-Hermans, M. J. W., van de Wal, M., Schirris, T., van Karnebeek, C., Pan, Y., & Koopman, W. J. H. (2021). The ketogenic diet as a therapeutic intervention strategy in mitochondrial disease. The International Journal of Biochemistry & Cell Biology, 138, 106050. https:\/\/doi.org\/10.1016\/j.biocel.2021.106050","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"key":"9800_CR142","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1749-6632.2009.04704.x","volume":"1171","author":"M Balietti","year":"2009","unstructured":"Balietti, M., Fattoretti, P., Giorgetti, B., Casoli, T., Di Stefano, G., Solazzi, M., Platano, D., Aicardi, G., & Bertoni-Freddari, C. (2009). A ketogenic diet increases succinic dehydrogenase activity in aging cardiomyocytes. Annals of the New York Academy of Sciences, 1171, 377\u2013384. https:\/\/doi.org\/10.1111\/j.1749-6632.2009.04704.x","journal-title":"Annals of the New York Academy of Sciences"},{"key":"9800_CR143","doi-asserted-by":"publisher","first-page":"111058","DOI":"10.1016\/j.exger.2020.111058","volume":"140","author":"Y Yu","year":"2020","unstructured":"Yu, Y., Wang, F., Wang, J., Zhang, D., & Zhao, X. (2020). Ketogenic diet attenuates aging-associated myocardial remodeling and dysfunction in mice. Experimental gerontology, 140, 111058. https:\/\/doi.org\/10.1016\/j.exger.2020.111058","journal-title":"Experimental gerontology"},{"issue":"2","key":"9800_CR144","doi-asserted-by":"publisher","first-page":"229","DOI":"10.14336\/AD.2019.0510","volume":"11","author":"Y Guo","year":"2020","unstructured":"Guo, Y., Zhang, C., Shang, F.-F., Luo, M., You, Y., Zhai, Q., Xia, Y., & Suxin, L. (2020). Ketogenic Diet ameliorates cardiac dysfunction via balancing mitochondrial dynamics and Inhibiting apoptosis apoptosis in type 2 diabetic. Aging Dis, 11(2), 229\u2013240. https:\/\/doi.org\/10.14336\/AD.2019.0510","journal-title":"Aging Dis"},{"issue":"12","key":"9800_CR145","doi-asserted-by":"publisher","first-page":"158813","DOI":"10.1016\/j.bbalip.2020.158813","volume":"1865","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk, G. D., Karwi, Q. G., Ho, K. L., Pherwani, S., & Ketema, E. B. (2020). Ketone metabolism in the failing heart. Biochimica et Biophysica acta Molecular and cell biology of lipids, 1865(12), 158813. https:\/\/doi.org\/10.1016\/j.bbalip.2020.158813","journal-title":"Biochimica et Biophysica acta Molecular and cell biology of lipids"},{"issue":"4","key":"9800_CR146","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2143\/AC.62.4.2022282","volume":"62","author":"NS Al-Zaid","year":"2007","unstructured":"Al-Zaid, N. S., Dashti, H. M., Mathew, T. C., & Juggi, J. S. (2007). Low carbohydrate ketogenic diet enhances cardiac tolerance to global ischaemia. Acta Cardiologica, 62(4), 381\u2013389.","journal-title":"Acta Cardiologica"},{"issue":"1","key":"9800_CR147","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11064-018-2588-6","volume":"44","author":"MM Hasan-Olive","year":"2019","unstructured":"Hasan-Olive, M. M., Lauritzen, K. H., Ali, M., Rasmussen, L. J., Storm-Mathisen, J., & Bergersen, L. H. (2019). A ketogenic diet improves mitochondrial biogenesis and bioenergetics via the PGC1\u03b1-SIRT3-UCP2 Axis. Neurochemical Research, 44(1), 22\u201337. https:\/\/doi.org\/10.1007\/s11064-018-2588-6","journal-title":"Neurochemical Research"},{"key":"9800_CR148","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2513837","author":"L Ji","year":"2022","unstructured":"Ji, L., He, Q., Liu, Y., Deng, Y., Xie, M., Luo, K., Cai, X., Zuo, Y., Wu, W., Li, Q., Zhou, R., & Li, T. (2022). Ketone Body -hydroxybutyrate prevents myocardial oxidative stress in septic cardiomyopathy. Oxidative Medicine and Cellular Longevity. https:\/\/doi.org\/10.1155\/2022\/2513837","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"1","key":"9800_CR149","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ijcard.2006.04.076","volume":"117","author":"A Ascens\u00e3o","year":"2007","unstructured":"Ascens\u00e3o, A., Ferreira, R., & Magalh\u00e3es, J. (2007). Exercise-induced cardioprotection\u2013biochemical, morphological and functional evidence in whole tissue and isolated mitochondria. International Journal of Cardiology, 117(1), 16\u201330. https:\/\/doi.org\/10.1016\/j.ijcard.2006.04.076","journal-title":"International Journal of Cardiology"},{"key":"9800_CR150","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.freeradbiomed.2020.04.005","volume":"152","author":"D Boulghobra","year":"2020","unstructured":"Boulghobra, D., Coste, F., Geny, B., & Reboul, C. (2020). Exercise training protects the heart against ischemia-reperfusion injury: A central role for mitochondria? Free Radical Biology & Medicine, 152, 395\u2013410. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2020.04.005","journal-title":"Free Radical Biology & Medicine"},{"issue":"1","key":"9800_CR151","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s00395-021-00906-3","volume":"116","author":"D Boulghobra","year":"2021","unstructured":"Boulghobra, D., Dubois, M., Alpha-Bazin, B., Coste, F., Olmos, M., Gayrard, S., Bornard, I., Meyer, G., Gaillard, J. C., Armengaud, J., & Reboul, C. (2021). Increased protein S-nitrosylation in mitochondria: A key mechanism of exercise-induced cardioprotection. Basic research in cardiology, 116(1), 66. https:\/\/doi.org\/10.1007\/s00395-021-00906-3","journal-title":"Basic research in cardiology"},{"issue":"3","key":"9800_CR152","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1249\/MSS.0b013e318231c037","volume":"44","author":"Y Lee","year":"2012","unstructured":"Lee, Y., Min, K., Talbert, E. E., Kavazis, A. N., Smuder, A. J., Willis, W. T., & Powers, S. K. (2012). Exercise protects cardiac mitochondria against ischemia-reperfusion injury. Medicine and Science in Sports and Exercise, 44(3), 397\u2013405. https:\/\/doi.org\/10.1249\/MSS.0b013e318231c037","journal-title":"Medicine and Science in Sports and Exercise"},{"issue":"2","key":"9800_CR153","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1152\/ajpheart.01231.2007","volume":"294","author":"AN Kavazis","year":"2008","unstructured":"Kavazis, A. N., McClung, J. M., Hood, D. A., & Powers, S. K. (2008). Exercise induces a cardiac mitochondrial phenotype that resists apoptotic stimuli. American Journal of Physiology Heart and Circulatory Physiology, 294(2), 928\u2013935. https:\/\/doi.org\/10.1152\/ajpheart.01231.2007","journal-title":"American Journal of Physiology Heart and Circulatory Physiology"},{"key":"9800_CR154","doi-asserted-by":"publisher","first-page":"114171","DOI":"10.1016\/j.biopha.2022.114171","volume":"159","author":"X Chang","year":"2023","unstructured":"Chang, X., Liu, J., Wang, Y., Guan, X., & Liu, R. (2023). Mitochondrial disorder and treatment of ischemic cardiomyopathy: Potential and advantages of Chinese herbal medicine. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 159, 114171. https:\/\/doi.org\/10.1016\/j.biopha.2022.114171","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"issue":"4","key":"9800_CR155","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.7150\/thno.43895","volume":"11","author":"L Jiang","year":"2021","unstructured":"Jiang, L., Yin, X., Chen, Y. H., Chen, Y., Jiang, W., Zheng, H., Huang, F. Q., Liu, B., Zhou, W., Qi, L. W., & Li, J. (2021). Proteomic analysis reveals ginsenoside Rb1 attenuates myocardial ischemia\/reperfusion injury through inhibiting ROS production from mitochondrial complex I. Theranostics, 11(4), 1703\u20131720. https:\/\/doi.org\/10.7150\/thno.43895","journal-title":"Theranostics"},{"key":"9800_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2015.11.003","author":"G Dong","year":"2016","unstructured":"Dong, G., Chen, T., Ren, X., Zhang, Z., Huang, W., Liu, L., Luo, P., & Zhou, H. (2016). Rg1 prevents myocardial hypoxia\/reoxygenation injury by regulating mitochondrial dynamics imbalance via modulation of glutamate dehydrogenase and mitofusin 2. Mitochondrion. https:\/\/doi.org\/10.1016\/j.mito.2015.11.003","journal-title":"Mitochondrion"},{"issue":"7","key":"9800_CR157","doi-asserted-by":"publisher","first-page":"855","DOI":"10.4161\/auto.6.7.13005","volume":"6","author":"MN Quinsay","year":"2010","unstructured":"Quinsay, M. N., Thomas, R. L., Lee, Y., & Gustafsson, A. B. (2010). Bnip3-mediated mitochondrial autophagy is independent of the mitochondrial permeability transition pore. Autophagy, 6(7), 855\u2013862. https:\/\/doi.org\/10.4161\/auto.6.7.13005","journal-title":"Autophagy"},{"key":"9800_CR158","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.biocel.2014.05.009","volume":"53","author":"CS Liu","year":"2014","unstructured":"Liu, C. S., Chang, J. C., Kuo, S. J., Liu, K. H., Lin, T. T., Cheng, W. L., & Chuang, S. F. (2014). Delivering healthy mitochondria for the therapy of mitochondrial diseases and beyond. The International Journal of Biochemistry & Cell Biology, 53, 141\u2013146. https:\/\/doi.org\/10.1016\/j.biocel.2014.05.009","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"1","key":"9800_CR159","doi-asserted-by":"publisher","first-page":"H94","DOI":"10.1152\/ajpheart.00567.2008","volume":"296","author":"JD McCully","year":"2009","unstructured":"McCully, J. D., Cowan, D. B., Pacak, C. A., Toumpoulis, I. K., Dayalan, H., & Levitsky, S. (2009). Injection of isolated mitochondria during early reperfusion for cardioprotection. American Journal Of Physiology Heart and Circulatory Physiology, 296(1), H94-h105. https:\/\/doi.org\/10.1152\/ajpheart.00567.2008","journal-title":"American Journal Of Physiology Heart and Circulatory Physiology"},{"key":"9800_CR160","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-55330-6_31","author":"B Shin","year":"2017","unstructured":"Shin, B., Cowan, D. B., Emani, S. M., Del Nido, P. J., & McCully, J. D. (2017). Mitochondrial Transplantation in Myocardial Ischemia and Reperfusion Injury. Advances in Experimental Medicine and Biology. https:\/\/doi.org\/10.1007\/978-3-319-55330-6_31","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"8","key":"9800_CR161","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41571-020-0367-1","volume":"17","author":"DM Ross","year":"2020","unstructured":"Ross, D. M., & Hughes, T. P. (2020). Treatment-free remission in patients with chronic myeloid leukaemia. Nature reviews Clinical oncology, 17(8), 493\u2013503. https:\/\/doi.org\/10.1038\/s41571-020-0367-1","journal-title":"Nature reviews Clinical oncology"},{"issue":"23","key":"9800_CR162","doi-asserted-by":"publisher","first-page":"8931","DOI":"10.1002\/cam4.3516","volume":"9","author":"E Sato","year":"2020","unstructured":"Sato, E., Iriyama, N., Tokuhira, M., Takaku, T., Ishikawa, M., Nakazato, T., Sugimoto, K. J., Fujita, H., Kimura, Y., Fujioka, I., Asou, N., Komatsu, N., Kizaki, M., Hatta, Y., & Kawaguchi, T. (2020). The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort. Cancer Medicine, 9(23), 8931\u20138939. https:\/\/doi.org\/10.1002\/cam4.3516","journal-title":"Cancer Medicine"},{"issue":"4","key":"9800_CR163","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., Hjorth-Hansen, H., Hughes, T. P., Janssen, J., Kantarjian, H. M., Kim, D. W., Larson, R. A., Lipton, J. H., Mahon, F. X., Mayer, J., \u2026 Hehlmann, R. (2020). European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia, 34(4), 966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"issue":"3","key":"9800_CR164","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-018-9578-9","volume":"45","author":"T Vaidya","year":"2018","unstructured":"Vaidya, T., Kamta, J., Chaar, M., Ande, A., & Ait-Oudhia, S. (2018). Systems pharmacological analysis of mitochondrial cardiotoxicity induced by selected tyrosine kinase inhibitors. Journal of Pharmacokinetics and Pharmacodynamics, 45(3), 401\u2013418. https:\/\/doi.org\/10.1007\/s10928-018-9578-9","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"10","key":"9800_CR165","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1056\/NEJMc1908886","volume":"381","author":"RI Henkin","year":"2019","unstructured":"Henkin, R. I. (2019). Clinical and therapeutic implications of cancer stem cells. New England Journal of Medicine, 381(10), 19. https:\/\/doi.org\/10.1056\/NEJMc1908886","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"9800_CR166","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","volume":"61","author":"J Schoepfer","year":"2018","unstructured":"Schoepfer, J., Jahnke, W., Berellini, G., Buonamici, S., Cotesta, S., Cowan-Jacob, S. W., Dodd, S., Drueckes, P., Fabbro, D., Gabriel, T., Groell, J.-M., Grotzfeld, R. M., Hassan, A. Q., Henry, C., Iyer, V., Jones, D., Lombardo, F., Loo, A., Manley, P. W., \u2026 Furet, P. (2018). Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. Journal of Medicinal Chemistry, 61(18), 8120\u20138135. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01040","journal-title":"Journal of Medicinal Chemistry"},{"issue":"21","key":"9800_CR167","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D R\u00e9a","year":"2021","unstructured":"R\u00e9a, D., Mauro, M. J., Boquimpani, C., Minami, Y., Lomaia, E., Voloshin, S., Turkina, A., Kim, D. W., Apperley, J. F., Abdo, A., Fogliatto, L. M., Kim, D. D. H., le Coutre, P., Saussele, S., Annunziata, M., Hughes, T. P., Chaudhri, N., Sasaki, K., Chee, L., \u2026 Hochhaus, A. (2021). A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood, 138(21), 2031\u20132041. https:\/\/doi.org\/10.1182\/blood.2020009984","journal-title":"Blood"},{"issue":"11","key":"9800_CR168","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/s2352-3026(22)00246-0","volume":"9","author":"H Kantarjian","year":"2022","unstructured":"Kantarjian, H., Paul, S., Thakkar, J., & Jabbour, E. (2022). The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA. The Lancet Haematology, 9(11), 854\u2013861. https:\/\/doi.org\/10.1016\/s2352-3026(22)00246-0","journal-title":"The Lancet Haematology"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-023-09800-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-023-09800-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-023-09800-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T11:11:48Z","timestamp":1692270708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-023-09800-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":168,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["9800"],"URL":"https:\/\/doi.org\/10.1007\/s12012-023-09800-x","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"3 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Research Involving Human and Animal Rights. This article does not contain human or animal studies performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human and Animal Rights participants"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}